Opinion: Pivot to J&J vaccine makes sense in light of new findings
Government deserves criticism for various aspects of its COVID-19 response, but some social media criticism following Sunday’s announcement that the Oxford University/AstraZeneca vaccine has little or no efficacy in preventing mild-to-moderate disease caused by the 501Y.V2 variant has been unfair, writes Marcus Low.
